Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists-Reference-Cited by-同舟云学术

Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists

Published:2016-03-30 Issue:6 Volume:32 Page:497-511
ISSN:1520-7552
Container-title:Diabetes/Metabolism Research and Reviews
language:en
Short-container-title:Diabetes Metab Res Rev

Author:

Giorgino Francesco¹,Bonadonna Riccardo C.²,Gentile Sandro³,Vettor Roberto⁴,Pozzilli Paolo⁵

Affiliation:

1. Dipartimento dell'Emergenza e dei Trapianti di Organi, Sezione di Medicina Interna, Endocrinologia, Andrologia e Malattie Metaboliche Università degli Studi di Bari Aldo Moro Bari Italy

2. Dipartimento di Medicina Clinica e Sperimentale, Divisione di Endocrinologia Università degli Studi di Parma, and AOU di Parma Parma Italy

3. Dipartimento di Medicina Clinica e Sperimentale Seconda Università degli Studi di Napoli Naples Italy

4. Dipartimento di Medicina – DIMED, Clinica Medica 3 Università di Padova Padova Italy

5. Department of Endocrinology & Diabetes Università Campus Bio‐Medico Rome Italy

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/dmrr.2775

Reference106 articles.

1. When basal insulin therapy in type 2 diabetes mellitus is not enough—what next?

2. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

3. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

4. Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers

5. Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics of subjects with type 2 diabetes enrolled in randomized controlled trials and non‐ randomized controlled trials in Japan: A systematic review;Journal of Diabetes Investigation;2022-12-20

2. Efectos en vida real de la adición de semaglutida subcutánea semanal al tratamiento con insulina en diabetes mellitus tipo 2;Revista Clínica Española;2022-11

3. Real-life effects of adding weekly subcutaneous semaglutide to insulin for the treatment of type 2 diabetes mellitus;Revista Clínica Española (English Edition);2022-11

4. IDegLira for the Real-World Treatment of Type 2 Diabetes in Italy: Protocol and Interim Results from the REX Observational Study;Diabetes Therapy;2022-06-18

5. Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies;Nutrition, Metabolism and Cardiovascular Diseases;2021-06